文献速递支持与姑息治疗

整合姑息与肿瘤治疗对急性髓系白血病患者的效果:一项随机临床试验

Effectiveness of Integrated Palliative and Oncology Care for Patients With Acute Myeloid Leukemia: A Randomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2021-01-01

这项多中心随机临床试验纳入160例接受强化化疗的急性髓系白血病患者,评估整合姑息与肿瘤治疗(IPC)对比常规护理对患者报告结局和临终结局的影响。结果显示IPC组在第2周生活质量更好、抑郁焦虑及PTSD症状更轻,且效果维持至第24周;IPC组临终前讨论偏好比例更高、最后30天接受化疗比例更低。

要点

  • IPC改善AML强化化疗患者第2周生活质量并减轻抑郁、焦虑和PTSD症状。
  • IPC的获益维持至第24周,涵盖生活质量及心理痛苦各维度。
  • IPC提高临终关怀偏好讨论率并减少生命最后30天化疗使用。

核心结论

  • 在AML强化化疗患者中,IPC显著改善生活质量、心理痛苦和临终关怀。
  • 研究者认为姑息治疗应被视为AML患者的新标准治疗。

研究设计与样本

  • 多中心随机临床试验,2017年1月至2019年7月在美国4家三级学术医院开展。
  • 纳入160例接受强化化疗的AML患者,IPC组86例,常规护理组74例。
  • IPC组在初次及后续住院期间每周至少接受2次姑息治疗临床医生访视。

主要发现

  • 死亡患者中IPC组讨论临终关怀偏好比例21/28(75.0%)vs 12/30(40.0%)(P=0.01)。
  • 死亡患者中IPC组最后30天接受化疗比例15/43(34.9%)vs 27/41(65.9%)(P=0.01)。

临床怎么用

  • 对接受强化化疗的AML患者,可在初次及后续住院期间整合每周至少2次的姑息治疗访视。
  • 采用FACT-Leukemia、HADS和PTSD Checklist-Civilian量表动态评估患者报告结局。
  • 主动与患者讨论临终关怀偏好,以降低生命最后30天的化疗使用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Patients with acute myeloid leukemia (AML) receiving intensive chemotherapy experience substantial decline in their quality of life (QOL) and mood during their hospitalization for induction chemotherapy and often receive aggressive care at the end of life (EOL). However, the role of specialty palliative care for improving the QOL and care for this population is currently unknown. OBJECTIVE: To assess the effect of integrated palliative and oncology care (IPC) on patient-reported and EOL outcomes in patients with AML. DESIGN, SETTING, AND PARTICIPANTS: We conducted a multisite randomized clinical trial of IPC (n = 86) vs usual care (UC) (n = 74) for patients with AML undergoing intensive chemotherapy. Data were collected from January 2017 through July 2019 at 4 tertiary care academic hospitals in the United States. INTERVENTIONS: Patients assigned to IPC were seen by palliative care clinicians at least twice per week during their initial and subsequent hospitalizations. MAIN OUTCOMES AND MEASURES: Patients completed the 44-item Functional Assessment of Cancer Therapy-Leukemia scale (score range, 0-176) to assess QOL; the 14-item Hospital Anxiety and Depression Scale (HADS), with subscales assessing symptoms of anxiety and depression (score range, 0-21); and the PTSD Checklist-Civilian version to assess posttraumatic stress disorder (PTSD) symptoms (score range, 17-85) at baseline and weeks 2, 4, 12, and 24. The primary end point was QOL at week 2. We used analysis of covariance adjusting and mixed linear effect models to evaluate patient-reported outcomes. We used Fisher exact test to compare patient-reported discussion of EOL care preferences and receipt of chemotherapy in the last 30 days of life. RESULTS: Of 235 eligible patients, 160 (68.1%) were enrolled; of the 160 participants, the median (range) age was 64.4 (19.7-80.1) years, and 64 (40.0%) were women. Compared with those receiving UC, IPC participants reported better QOL (adjusted mean score, 107.59 vs 116.45; P = .04), and lower depression (adjusted mean score, 7.20 vs 5.68; P = .02), anxiety (adjusted mean score, 5.94 vs 4.53; P = .02), and PTSD symptoms (adjusted mean score, 31.69 vs 27.79; P = .01) at week 2. Intervention effects were sustained to week 24 for QOL (β, 2.35; 95% CI, 0.02-4.68; P = .048), depression (β, -0.42; 95% CI, -0.82 to -0.02; P = .04), anxiety (β, -0.38; 95% CI, -0.75 to -0.01; P = .04), and PTSD symptoms (β, -1.43; 95% CI, -2.34 to -0.54; P = .002). Among patients who died, those receiving IPC were more likely than those receiving UC to report discussing EOL care preferences (21 of 28 [75.0%] vs 12 of 30 [40.0%]; P = .01) and less likely to receive chemotherapy near EOL (15 of 43 [34.9%] vs 27 of 41 [65.9%]; P = .01). CONCLUSIONS AND RELEVANCE: In this randomized clinical trial of patients with AML, IPC led to substantial improvements in QOL, psychological distress, and EOL care. Palliative care should be considered a new standard of care for patients with AML. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02975869.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. El-Jawahri A, LeBlanc TW, Kavanaugh A, et al. Effectiveness of Integrated Palliative and Oncology Care for Patients With Acute Myeloid Leukemia: A Randomized Clinical Trial. JAMA Oncol. 2021. PMID: 33331857. doi:10.1001/jamaoncol.2020.6343

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。